A Phase 2 interventional study of Ensifentrine 3 mg and Glycopyrrolate 21.25 mcg in Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Completed at 57 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 13th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 497 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 79 across the 15 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 4 most frequent:
This study is registered under Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 6th largest by enrollment, is one of 2 that started in 2025, is one of 18 in phase 2, and was the 24th registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult participants with chronic obstructive pulmonary disease (COPD).
Enrolled participants will be expected to participate for approximately 7 weeks: 1 to 2 weeks for screening, 4 weeks of treatment, and 1 week of follow up. Participants will be randomized to one of 6 treatment arms: two fixed dose combinations of ensifentrine (3 mg) and glycopyrrolate (either 21.25 or 42.5 mcg), the 3 individual components as monotherapies, or placebo. All treatments will be administered twice a day via oral inhalation by a standard jet nebulizer. The primary objective of this study is to evaluate the bronchodilator effects of the fixed dose combinations compared to each of the individual components and to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females are eligible to participate if they are not pregnant, breastfeeding and if one of the following conditions apply:
Post-bronchodilator (4 puffs of albuterol) spirometry during the Screening Period demonstrating both the following:
Exclusion Criteria:
Severe comorbidities including
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ensifentrine 3 mg / glycopyrrolate 42.5 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.
Drug: Ensifentrine 3 mg · Drug: Glycopyrrolate 42.5 mcg
Participants will receive ensifentrine 3 mg / glycopyrrolate 21.25 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.
Drug: Ensifentrine 3 mg · Drug: Glycopyrrolate 21.25 mcg
Participants will receive glycopyrrolate monotherapy 42.5 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.
Drug: Glycopyrrolate 42.5 mcg
Participants will receive glycopyrrolate monotherapy 21.25 mcg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.
Drug: Glycopyrrolate 21.25 mcg
Participants will receive ensifentrine monotherapy 3 mg twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.
Drug: Ensifentrine 3 mg
Participants will receive placebo twice a day for up to 28 days via oral inhalation by a standard jet nebulizer.
Drug: Placebo
Administered by a standard jet nebulizer, twice daily for 28 consecutive days
Administered by a standard jet nebulizer, twice daily for 28 consecutive days
Administered by a standard jet nebulizer, twice daily for 28 consecutive days
Administered by a standard jet nebulizer, twice daily for 28 consecutive days
Change From Baseline in Average Forced Expiry Volume in 1 Second (FEV1) Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)
Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 4 hours on Day 28 will be reported.
Time frame: Baseline and Day 28
Change From Baseline in Peak FEV1 Measured Over 4 Hours Post-Dose
Spirometry will be performed to determine the FEV1. Change from baseline in peak FEV1 over 4 hours following dosing on Day 28 will be reported.
Time frame: Baseline and Day 28
Change From Baseline in Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h)
Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 12 hours on Day 28 will be reported.
Time frame: Baseline and Day 28
Change From Baseline in Morning Trough FEV1 on Day 29
Spirometry will be performed to determine the FEV1. Change from baseline in morning trough FEV1 measured on Day 29 will be reported.
Time frame: Baseline and Day 29
Change From Baseline in Evening Trough FEV1 on Day 28
Spirometry will be performed to determine the FEV1. Change from baseline in evening trough FEV1 measured on Day 28 will be reported.
Time frame: Baseline and Day 28
Change From Baseline in Morning Trough FEV1 on Day 28
Spirometry will be performed to determine the FEV1. Change from baseline in morning trough FEV1 measured on Day 28 will be reported.
Time frame: Baseline and Day 28
Change From Baseline in Average FEV1 AUC0-4h Measured After First Dose on Day 14
Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 4 hours following the first dose on Day 14 will be reported.
Time frame: Baseline and Day 14
Change From Baseline in Peak FEV1 Measured Over 4 Hours After First Dose on Day 14
Spirometry will be performed to determine the FEV1. Change from baseline in peak FEV1 over 4 hours following the first dose on Day 14 will be reported.
Time frame: Baseline and Day 14
Change From Baseline in Average FEV1 AUC0-4h Measured After First Dose on Day 1
Spirometry will be performed to determine the FEV1. Change from baseline in average FEV1 area under the curve from 0 to 4 hours following the first dose on Day 1 will be reported.
Time frame: Baseline and Day 1
Change from Baseline in Peak FEV1 Measured Over 4 Hours After First Dose on Day 1
Spirometry will be performed to determine the FEV1. Change from baseline in peak FEV1 over 4 hours following the first dose on Day 1 will be reported.
Time frame: Baseline and Day 1
Change in Symptoms of Dyspnea from Baseline as Measured by Transition Dyspnea Index (TDI) Score on Day 14
The TDI measures the change in dyspnea symptom severity from the baseline as measured by the Baseline Dyspnea Index (BDI). It is based on three components, functional impairment, magnitude of task, and magnitude of effort, that evoke dyspnea in activities of daily living. The BDI score ranges from 0 (very severe impairment) to 4 (no impairment) for each domain and are summed to determine the BDI focal score (0-12). The TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain. The sum of all domains yields the TDI focal score (-9 to +9). Change from baseline in TDI score on Day 14 will be reported.
Time frame: Baseline and Day 14
Change in Symptoms of Dyspnea from Baseline as Measured by TDI Score on Day 28
The TDI measures the change in dyspnea symptom severity from the baseline as measured by the BDI. It is based on three components, functional impairment, magnitude of task, and magnitude of effort, that evoke dyspnea in activities of daily living. The BDI score ranges from 0 (very severe impairment) to 4 (no impairment) for each domain and are summed to determine the BDI focal score (0-12). The TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain. The sum of all domains yields the TDI focal score (-9 to +9). Change from baseline in TDI score on Day 28 will be reported.
Time frame: Baseline and Day 28
Change From Baseline in Health-Related Quality of Life as Measured by Saint George's Respiratory Questionnaire (SGRQ) Total Score
The SGRQ Patient Reported Outcome (PRO) measure is a 50- item questionnaire designed to assess health-related quality of life in patients with COPD in terms of symptoms, daily activity limitation, and psychosocial well-being. The total score ranges from 0 to 100, with lower scores indicating better health status. Change from baseline in health-related quality of life as assessed using SGRQ total score on Day 28 will be reported.
Time frame: Baseline and Day 28
Number of Participants who Experience at Least one Treatment Emergent Adverse Event (TEAE)
An AE is any untoward medical occurrence in a subject, temporally associated with the use of the study medication, whether or not considered related to the study medication. Number of participants who experience at least one TEAE will be reported.
Time frame: Up to approximately 5 weeks
Number of Participants With Markedly Abnormal Changes in Hematology Parameters
Number of participants with markedly abnormal changes in hematology parameters will be reported.
Time frame: Up to approximately Day 28
Number of Participants With Markedly Abnormal Changes in Blood Chemistry Parameters
Number of participants with markedly abnormal changes in blood chemistry parameters will be reported.
Time frame: Up to approximately Day 28
Number of Participants With Markedly Abnormal Changes in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
Number of participants with markedly abnormal changes in QTcF measurements will be reported.
Time frame: Up to approximately Day 28
Number of Participants With Markedly Abnormal Changes in Heart Rate
Number of participants with markedly abnormal changes in heart rate will be reported.
Time frame: Up to approximately Day 28
Number of Participants With Markedly Abnormal Changes in Blood Pressure
Number of participants with markedly abnormal changes in blood pressure will be reported.
Time frame: Up to approximately Day 28
Number of Participants With Markedly Abnormal Changes in Pulse Rate
Number of participants with markedly abnormal changes in pulse rate will be reported.
Time frame: Up to approximately Day 28
Area Under the Concentration-Time Curve from Time 0 to 12 Hours (AUC0-12hrs) of Ensifentrine
Blood samples will be collected to determine the AUC0-12hrs of ensifentrine.
Time frame: Predose and at designated timepoints up to 12 hours postdose
Maximum Plasma Concentration (Cmax) of Ensifentrine
Blood samples will be collected to determine the Cmax of ensifentrine.
Time frame: Predose and at designated timepoints up to day 28 postdose
Plasma Trough Concentration (Ctrough) of Ensifentrine
Blood samples will be collected to determine the Ctrough of ensifentrine.
Time frame: Day 28
Average Plasma Concentrations (Cavg) of Ensifentrine
Blood samples will be collected to determine the Cavg of ensifentrine.
Time frame: Day 28
Time to Maximum Plasma Concentration (Tmax) of Ensifentrine
Blood samples will be collected to determine the Tmax of ensifentrine.
Time frame: Predose and at designated timepoints up to day 28 postdose
Apparent Clearance (CL/F) of Ensifentrine
Blood samples will be collected to determine the CL/F of ensifentrine.
Time frame: Day 28
Accumulation Ratio Cmax (ARCmax) of Ensifentrine
Blood samples will be collected to determine the ARCmax of ensifentrine.
Time frame: Predose and at designated timepoints up to day 28 postdose
Accumulation Ratio AUC (ARAUCs) of Ensifentrine
Blood Samples Will be Collected to Determine the ARAUC of Ensifentrine.
Time frame: Predose and at designated timepoints up to day 28 postdose
Area Under the Concentration-Time Curve from Time 0 to 12 Hours (AUC0-12hrs) of Glycopyrronium
Blood samples will be collected to determine the AUC0-12hrs of glycopyrronium.
Time frame: Predose and at designated timepoints up to 12 hours postdose
Maximum Plasma Concentration (Cmax) of Glycopyrronium
Blood samples will be collected to determine the Cmax of glycopyrronium.
Time frame: Predose and at designated timepoints up to day 28 postdose
Plasma Trough Concentration (Ctrough) of Glycopyrronium
Blood samples will be collected to determine the Ctrough of glycopyrronium.
Time frame: Day 28
Average Plasma Concentrations (Cavg) of Glycopyrronium
Blood samples will be collected to determine the Cavg of glycopyrronium.
Time frame: Day 28
Time to Maximum Plasma Concentration (Tmax) of Glycopyrronium
Blood samples will be collected to determine the Tmax of glycopyrronium.
Time frame: Predose and at designated timepoints up to day 28 postdose
Apparent Clearance (CL/F) of Glycopyrronium
Blood samples will be collected to determine the CL/F of glycopyrronium.
Time frame: Day 28
Accumulation Ratio Cmax (ARCmax) of Glycopyrronium
Blood samples will be collected to determine the ARCmax of glycopyrronium.
Time frame: Predose and at designated timepoints up to day 28 postdose
Accumulation Ratio AUC (ARAUCs) of Glycopyrronium
Blood Samples Will be Collected to Determine the ARAUC of glycopyrronium.
Time frame: Predose and at designated timepoints up to day 28 postdose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2025 to primary completion in Aug 2026, 12 months.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 12 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ensifentrine · Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA →